Profile-QSAR (pQSAR) is a massively multi-task, 2-step machine learning method with unprecedented scope, accuracy and applicability domain. In step one, a "profile" of conventional single-assay random forest regression (RFR) models are trained on a very large number of biochemical and cellular pIC50 assays using Morgan 2 sub-structural fingerprints as compound descriptors. In step two, a panel of PLS models are built using the profile of pIC50 predictions from those RFR models as compound descriptors. Hence the name. Previously described for a panel of 728 biochemical and cellular kinase assays, we have now built an enormous pQSAR from 11,805 diverse Novartis IC50 and EC50 assays. This large number of assays, and hence of compound descriptors for PLS, dictated reducing the profile by only including RFR models whose predictions correlate with the assay being modeled. The RFR and pQSAR models were evaluated with our "realistically novel" held-out test set whose median average similarity to the nearest training set member across the 11,805 assays was only 0.34, thus testing a realistically large applicability domain. For the 11,805 single-assay RFR models, the median correlation of prediction with experiment was only R 2 ext=0.05, virtually random, and only 8% of the models achieved our standard success threshold of R 2 ext=0.30. For pQSAR, the median correlation was R 2 ext=0.53, comparable to 4-concentration experimental IC50s, and 72% of the models met our R 2 ext>0.30 standard, totaling 8558 successful models. The successful models included assays from all of the 51 annotated target sub-classes, as well as 4196 phenotypic assays, indicating that pQSAR can be applied to virtually any disease area. Every month, all models are updated to include new measurements, and predictions are made for 5.5 million Novartis compounds, totaling 50 billion predictions. Common uses have included virtual screening, selectivity design, toxicity and promiscuity prediction, mechanism-of-action prediction, and others.
INTRODUCTION
Developing accurate, predictive quantitative structure-activity relationship (QSAR) models with wide applicability domains, for most biological assays, has long been a goal of computational scientists. As computer power has increased, building QSAR models has become increasingly automated and robust.
1 However, while conventional, single-task QSARs can give accurate predictions for compounds very like the training set, such as random held-out test sets, they generally fail on the far more novel compounds project teams actually order for testing from virtual screens. Massively multi-task QSAR models improve the accuracy and applicability domain. 2 Additionally, studies 3, 4 have introduced in vitro biological assay information as descriptors in QSAR. Recent studies [5] [6] [7] employing experimental in vivo or in vitro test results as descriptors filled missing biological values using either pure chemical information 6, 7 or a mixture of chemical and biological data 5 .
compounds, and 18.3 million pIC 50 s. The final ChEMBL data included 4276 assays, 0.5 million compounds, and 1.4 million pIC 50 s. The distributions of assay size for NVS and ChEMBl are presented in Figure S1 . The specific assay identifiers for 4276 ChEMBL assays with corresponding number of compounds, assay type, and target family are listed in Supplemental Table S1 .
Realistic training/test set splits
The final production models for virtual screening are trained on all the data at every step. However, evaluating the quality of a model requires a held-out test set. The "realistic training/test set split"
was previously shown to mirror the novelty of the compounds that project teams ordered from actual virtual screens. 9 The previously described algorithm was ported from KNIME and ICM to python. The compounds are first clustered. For smaller assays, a hierarchical clustering is employed. For assays with more than 10,000 compounds, the Butina clustering algorithm 14 is used instead. The training set is collected starting with the largest cluster, and proceeding to successively smaller clusters until 75% of the compounds have been gathered. The remaining singletons and small clusters make up the "realistic" test set. The box plots in Figure S2 summarize histograms of the Tanimoto similarity (Tc) between the each test set member and the nearest training set member for realistic and random splitting of NVS and ChEMBL compounds.
pQSAR workflow
Figure 1 depicts the 2-step pQSAR 2.0 algorithm, as previously described for the kinase family. 9 First, conventional, SA RFR QSARs are trained for each assay on all available sparse historical activity data using scikit-learn 15 RandomForestRegressor (v0.20.2) . No test-set data are withheld in this step (see below). Parameters were defaults except the number of trees was set to 200.
Compound descriptors are RDkit (v2018.09.1.0) Morgan radius 2 substructure fingerprints with by all assays. In the second step of "FP pQSAR", these FPs of RFR predicted pIC 50 s are used as compound descriptors to train a PLS model for each assay, individually, using scikit-learn 15 PLSRegression (v0.20.2). For "reduced-profile" pQSAR, in order to reduce the compound's descriptor vectors for the PLS models in the second step, the training set experimental pIC 50 s for the assay currently being modeled are compared to predictions from the RFR models for each of the other assays. An assay is excluded from the reduced profile if the correlation does not reach a threshold, indicated by the greyed out columns in Figure 1 . Two models are built for each assay:
with thresholds of R 2 >0.2 and R 2 >0.05. The higher threshold generally gives better models, but for some assays that leaves few or no assays in the profile. It is not clear how many assays in the profile are ideal, so for simplicity, the model with the better R 2 ext on the test set is retained. We call this "max2". When evaluating pQSAR, just the training set compounds from the realistic training/test set split are used to train the PLS model. The assay being modeled, as well as RFR models that correlate with R 2 >0.99 with the assay being modeled, are excluded from the profile as indicated by the red "X". For predictions on new compounds, they are first run through the RFR models to generate the predicted pIC 50 profile, which is then run through the final PLS model to predict the activity.
Using models trained on each of the columns in the first RFR step, followed by a model based on the new row in the second PLS step, results in every experimental pIC 50 from the reduced profile informing every prediction. A custom model for a new assay does not require training additional RFR models. It only requires making RFR predictions for any new training compounds to add new rows to the existing profile matrix, then training a new PLS model. Of course, this new assay will not contribute to improving the models for other assays in the panel. The entire process including retraining of all SA RFR models is performed monthly, and at that time the new assay will contribute to the other models as well.
Y-scrambling
Y-scrambling 16 was used to estimate the number of apparently successful models that are actually due to chance correlations. Randomly reassigning the pIC 50 s among the structures for each assay were performed on both the NVS and ChEMBL data sets. SA RFR models were trained. As expected, few models had R 2 ext >0.3. Y-scrambled AA FP and AA max2 PLS Models were trained on these meaningless SA RFR "profiles", and the number of "successful" models (R 2 ext >0.30) was counted and analyzed for comparison with models built on the unscrambled data. AA FP and AA max2 PLS models for the Y-scrambled assay data were also trained on the "real" SA RFR profiles.
RESULTS AND DISCUSSION
A total of 11,805 dose-response assays measured on at least 50 unique compounds and with pIC 50 standard deviation greater than 0.5 were found in the NVS database. The experimental data included 1.8 million unique compounds, and 18.3 million IC 50 measurements. On average, each compound was measured on 10 assays and each assay was measured for 1550 compounds. The complete compound by assay matrix was only 0.1% complete. Timely pQSAR calculation on this large dataset required improvements in the implementation, including porting all KNIME, R and ICM code to python, although some infrastructure is still in C#. As seen from the bottom curve in Figure 2A , using the realistic training/test set split, 92% of these assays failed to produce successful to training set similarity for the realistic and random splits, respectively. We strongly recommend that the average test set similarity be reported whenever a performance metric is presented for a model, so the reader will understand the applicability domain for which the performance has been evaluated. This issue is well illustrated by the following ChEMBL performance summary. In order to present a non-proprietary analysis with full scientific reproducibility, the same criteria were employed to retrieve assays from the public ChEMBL database. The 4276 such assays, covering 500,000 compounds, included 1.4 million pIC 50 s, for a 0.1% complete matrix. However, the average compound was measured on only 2.8 assays and the average assay had only 327
compounds. Supplemental Table S2 lists ChEMBL (compound) ID, assay ID, observed pIC 50 s and max2 predicted pIC 50 s for the 1.4 million activity measurements. Supplemental Table S3 lists the RDkit canonical SMILES for the half million ChEMBL compounds. Figure 2B shows that 28% of these assays gave successful (R 2 ext >0.30) SA RFR models with a median correlation of R 2 ext =0.12, a much higher fraction than the NVS SA RFR models. This is partly due to more chance correlations (see below). However, this might mainly result from the much more homogeneous ChEMBL compound sets. The median across the 4276 assays of the average Tanimoto similarity between the realistic test and training sets was 0.63, much more similar than NVS. The median average random test set similarity is fully 0.77. This would seriously overestimate the performance for virtual screening where novelty is a compound selection criterion. The box plots in Figures   S2C and S2D summarize, for the ChEMBL assays, histograms of test set to training set similarity for the realistic and random splits.
As Figure 2B shows, FP pQSAR also greatly improved the ChEMBL results, although not as dramatically as in the NVS case, increasing the median correlation with experiment to R 2 ext =0.30
and 50% of the assays achieving successful models.
It is known that PLS models lose accuracy with increasing numbers of irrelevant descriptors.
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With 11,805 NVS SA RFR models in the AA FP as compound descriptors, but an average of 1,162
and sometimes as few as 37 training IC 50 s, the ratio of independent variables to observations reduces the performance even of a powerful latent-variable regression method like PLS. Methods to identify unhelpful RFR models and build reduced profile pQSARs were therefore explored. For simplicity, methods that would employ the same subset for all PLS models were tried first.
Predictions were not improved by using only SA RFR models trained on assays exceeding a minimal number of IC 50 s, or setting a minimum SA RFR R 2 ext .
The earlier family-specific (FS) pQSARs can be thought of as an intermediate case of reducing the profile, where the FP of SA RFR predictions from just a specific family was used for all pQSAR models from that family. Overall, these FS-FP pQSARs were equal or better, sometimes much better, than AA FP pQSARs. Yet, only one third of the assays are members of large families.
A more general method to reduce the profile was therefore sought that would also apply to the remaining two thirds of the assays from phenotypic screens or smaller families.
Methods that employed a tailored, reduced profile for each assay were therefore explored. An attractive feature of pQSAR is simplicity. It is a turnkey method with virtually no architecture or hyper-parameter retraining. Furthermore, well-known variable selection methods would be frustrated by the unique "realistic" training/test set split. I.e. hyper-parameters such as variable selections optimized against random subsets of the training set might not be optimal for the far more novel realistic test set. Finally, we wanted a simple method that ideally would decrease the compute resources of the second PLS step, by using smaller profiles, rather than increasing it with a laborious variable selection algorithm. An effective compromise was to test in advance of PLS, and only retain for each PLS model, the RFR models in the profile whose predicted pIC 50 s correlated with the experimental pIC 50 s in the dependent assay's training set. Higher thresholds generally gave better predictions, but some PLS models failed because there were few or no RFR models meeting the threshold. A simple compromise was to build PLS models using 2 thresholds:
.05, and use whichever gave the better final R 2 ext . We call this "max2". As Figure   2A shows, the AA max2 pQSAR median R of the assays meeting the success criterion as shown in Figure 2B . The predicted ChEMBL AA max2 pQSAR pIC 50 s are listed in Supplementary Table S2. For AA FP pQSAR, using the linear PLS regression method worked better than using the nonlinear RFR in the second step, as had been previously found for kinases. To further test this result, recursive random forest regression (RRFR) 18 , a method that combines variable reduction with RFR, was compared to max2 PLS. Figure S3 shows that the median R conclusions drawn by many other studies 19, 20 . This unusual result might be due to the larger extrapolations required by the realistic test set compared to the more usual random test sets. and FS-max2 are very close. AA-max2 produces more successful models in most cases, but FSmax2 produces more for GPCRs and NHRs. We do not consider the differences large enough to justify maintaining separate family-specific models.
Beyond the large target classes in Table 1 , there were at least some successful models from every one of the 51 smaller target sub-classes annotated in the database, indicating that pQSAR models can be used on virtually every target type. About half the models, both from NVS and ChEMBL, were phenotypic screens with no assigned target. These are particularly challenging for SA RFR models, with median R Transfer learning between NVS and ChEMBL profiles was tested by using the ChEMBL RFR profile to build PLS models for NVS assays ( Figure S4A ) and vice versa ( Figure S4B ). As was previously reported for kinases, pQSAR models for NVS assays trained using the ChEMBL AA FP profile and pQSAR models for ChEMBL assays trained using the AA FP NVS profile performed little better than simple SA RFR models. Cross-dataset predictions using max2 reduced profiles are only slightly better. Combined FPs perform almost as well as native FPs. Combined max2 profiles were no better or worse than native NVS or ChEMBL max2 profiles alone. Thus, combining RFR profiles is useful for expanding the applicability domains to cover both data sets, but does not improve the accuracy over the native models.
With so many compound descriptors, chance correlations were a concern. Several Y-scrambling protocols were performed to estimate chance correlations. Y-scrambling the entire AA max2 pQSAR procedure, including building the SA RFR models on Y-scrambled IC 50 data for each of the 11,805 assays, gave only 52 SA RFR and 47 AA max2 PLS models with R 2 ext >0.3. This is only 0.4% of the 11,805 assays. Not surprisingly, the largest of these assays contained only 81 pIC 50 s, so successful models built on larger assays are very unlikely by chance. Furthermore, 34 of those 47 "successful" AA max2 pQSAR models gave good models on real data. Given the tiny Yscrambling rate, these are undoubtedly actual good models. One could, therefore, anticipate that only 13 out of the 8558 successful models trained on real data, i.e. about 0.15%, are actually chance correlations, a remarkably low false positive rate. However, the above test is possibly too conservative, because the SA RFR matrix built on Yscrambled data should have almost no multicollinearity. i.e. the rank of the SA RFR predicted IC 50 profile matrix from Y-scrambled data is higher than that built from real data, and so has greater opportunity for chance correlations. The SA RFR profiles from the real data will still be independent of Y-scrambled training and test data in the PLS step. Three rounds of training Yscrambled FP PLS models using the real SA RFR profiles gave only 32 to 36 models with R 2 ext >0.3. One assay was shared between each pair of repetitions, and no assays were shared among all 3, indicating that these really were chance events. Training Y-scrambled max2 PLS models using the real SA RFR profiles gave 35 models with R 2 ext >0.3. Twenty-two of the assays that gave chance correlations with scrambled data gave good correlations with real data, so this test also suggests that about 13 of the 8558 successful models, or 0.15%, are chance correlations.
Y-scrambling the entire max2 pQSAR procedure for ChEMBL gave 97 SA RFR models and 175 max2 PLS models with R So far, only predictions on compounds with experimental data, that are in the SA RFR predicted IC 50 profile table, have been presented. To make predictions on new compounds, they are first run through the SA RFR models to obtain their predicted activity profiles. The new profiles are then used in one or more PLS equations to yield the max2 pQSAR activity predictions. While the chemical space covered by the archive drifts over time, the procedure is highly automated. Every month, all assay data are downloaded from the NVS database, the data are filtered and processed, and all of the nearly 12,000 pQSAR models are rebuilt from scratch as described above. Nearly 50 billion pIC 50 s are then predicted for the 5.5 million compounds in the NVS database against the 8558 successful models. These are loaded into a Databricks database for virtual screening and general data mining. Z-scaled pIC 50 predictions are also stored to facilitate comparison across assays, e.g. for predicting mechanism-of-action in phenotypic screens or potential off-target activities. The predictions are also stored in a specialized "descriptor store" database for use as continuous-valued fingerprints in clustering or other data analyses.
Prospective application examples
Over the last 15 years pQSAR, in its several incarnations, has been applied to well over 100 projects--initially for kinases and more recently for diverse targeted and phenotypic projects.
Applications have spanned drug discovery: virtual screening for tool compounds and medicinal chemistry starting points, selectivity calculation including isoform selectivity, hit list triaging, fragment hit expansion, toxicity and promiscuity prediction, mechanism-of-action prediction, virtual orthosteric counter-screens to identify allosteric inhibitors from experimental highthroughput screens, etc. A few examples below illustrate typical applications both from the original kinase pQSAR and AA FP pQSAR. Results from AA max2 projects are not yet available.
Raf kinase virtual screening
B-Raf provides an early kinase virtual screening example. The goal was to identify potential backup scaffolds from 600K compounds added to the corporate archive since an earlier full-deck high throughput screening (HTS). Being an advanced project, over 35,000 biochemical IC50s and cellular EC50s were available divided among 5 assays: the target kinase, a mutant variant prevalent in tumors, an isoform, a cell proliferation assay and a cellular target modulation assay measuring phosphorylation of downstream kinase ERK. Compounds with predicted pIC50 or pEC50 ≥ 6 by all 5 models were initially selected. Molecular weight and rotatable bond filters were applied, and compounds containing known Raf scaffolds were removed. The remaining compounds were clustered into 47 clusters and all cluster centers, as well as analogues with Tanimoto similarity coefficient (Tc) ≥ 0.8 to the cluster centers, were kept. Seventy-three compounds were sent for biochemical evaluation. Fifty-three had IC50 ≤ 10 µM, an overall 80% hit rate. The hit-count line in the novelty/hit-rate histogram (Figure 3 ) for this project shows that, per usual, none of the selected compounds were from within Tc>0.8 of the training compounds. The majority of hits had similarities less than 0.6, and shared no scaffolds with the nearest known active compounds. Hit rates were 60%-80% even for compounds with novel scaffolds and similarity Tc < 0.4 to any of the 35K known actives, 2 logs above the HTS background rate. Although the cell line was described as "driven" by mutant bRAF, cell proliferation can be modulated by multiple mechanisms. To look for other interfering kinases, pQSAR models were built for both the A375 TM and A375 CP assays using only a profile of 92 kinase biochemical models, without including cellular assays. The PLS coefficients for the TM and CP pQSAR models are plotted on the Sugen kinome dendrograms in Figure S5 . The diameters of the circles indicate the magnitudes of the PLS coefficients, blue indicating a positive contribution and red negative.
For the bRAF TM model, the 2 largest positive coefficients were bRAF (relative value = 1) and cRAF (relative value = 0.54), consistent with target modulation being driven primarily by RAF inhibition. In the cell proliferation assay, bRAF is still most important (relative value = 0.86), but some other tyrosine kinases (TK) also had large positive coefficients. PDGFRb (relative value = 0.71) was selected for further analysis. For many of the compounds inactive at the highest tested concentration of 10 µM (pIC50 < 5) in the CP assay, bRAFV599E biochemical pIC50 was high, but in these cases PDGFRb pIC50 < 6.5. Conversely, when A375 CP pEC50 > 5.5, both bRAFV599E and PDGFRb were above pIC50 ~ 7. Thus, the CP assay was most sensitive to bRAF/PDGFRb dual inhibitors. PDGFRs were reported to activate Ras via SHP2, making this interactions plausible 21 .
Morgan fingerprints, followed by PLS regression. However, one can easily replace or augment these 2D RFR models by additional 2D or 3D QSAR models, pharmacophore models or docking models in the first step, for a richer description of the chemistry. Similarly, additional column types such as physicochemical properties or genomics data can be added beside the assays for a richer description in the experimental dimension. Thus, there are myriad opportunities to extend the scope of pQSAR beyond this basic beginning.
CONCLUSIONS
pQSAR for single protein families was previously shown to far exceed single-assay QSAR models.
All assay pQSAR is a unified platform that included all of the 51 annotated target sub-classes, as well as 5506 phenotypic assays, which expands the applicability domain for idiosyncratic targets or phenotypic screens. AA max2 profile reduction further removes noise and enhances model performance. AA max2 also saves computation. The number of PLS descriptors was reduced by about 80% and 96% at the thresholds of R 2 =0.05 and R 2 =0.20, respectively, while achieving improved performance. This is a substantial computational resource saving when training 11,805 PLS models and predicting 5.5 million compounds on each. The negligible chance correlations indicate the reliability of AA max2 pQSAR models.
Nearly 50 billion pIC50s are predicted for the 5.5 million compounds in the NVS database against the 8558 successful models. The pQSAR models are updated monthly. As newly tested doseresponse pIC50s are continuously adding to NVS database, the number of successful models as well as the predicted pIC50s are expected to grow rapidly.
SUPPORTING INFORMATION
The curated pIC50s of 0.5 million compounds measured on 4276 ChEMBL assays as well as their prediction can be found in the supplementary materials. Table S1 . General information of 4276 ChEMBL assays. The specific assay identifiers, the number of tested compounds, corresponding assay type and target family. (TXT) 
